Financial Results of Steris during Q4 2025: Breakdown of Key Figures
Fresh Take:
Hey there! Let's dive into Steris' (STE) latest financials for Q4 2025. Here's a quick rundown.
Steris showed a robust performance in its fourth quarter, fueled by a revenue jump and improved profit margins. Want the nitty-gritty details? Check out the company's earnings press release.
- Revenue-wise, Steris scored a 4% year-on-year boost, reaching approximately $1.5 billion. This figure represents a 6% organic growth in constant currency[4][5].
- Earnings-wise, Steris' adjusted EPS clocked in at $2.74, signifying a significant 13.7%-14% increase compared to the previous year's quarter[2][5].
- Net income from ongoing operations amounted to $270 million for the quarter[5].
Now, let's talk segment-wise:
- Healthcare segment's revenue rose by 5-6% (6% constant currency organic growth), clocking in around $1.1 billion[4][5].
- Applied Sterilization Technologies (AST) saw a 9% revenue surge, hitting approximately $273.9 million[4].
- The Life Sciences segment experienced a 7% decline in revenue, dropping to about $149.5 million[4].
Steris also managed to enhance its profit margins:
- Gross margin swelled by 170 basis points to 44.3% in Q4 2025[5].
- EBIT margin grew by 110 basis points, accounting for 24.8% of revenue[5].
Looking at the big picture for fiscal year 2025:
- Steris reported a $5.5 billion revenue, marking a 6% increase from the previous year[4].
- Net income for the year was $610.1 million, or $6.16 per diluted share[4].
- Adjusted EPS was $9.22[4].
- The company's free cash flow was strong at $787.2 million[4][5].
- Capital expenditures for the year totaled $370 million, with depreciation and amortization adding up to $476 million[5].
- Total debt amounted to around $2 billion at quarter end, with a gross debt to EBITDA ratio of about 1.4 times[5].
For fiscal 2026, Steris anticipates revenue growth between 6-7% and an adjusted EPS ranging from $9.90 to $10.15. The company also estimates a $30 million negative impact from tariffs[4]. All in all, Steris is optimistic about its future growth prospects.
Investing in Steris (STE) could be a promising move in the finance sector, given its strong Q4 2025 performance, with a 4% revenue increase and a significant boost in adjusted EPS by 13.7-14%. For those interested, delve into the company's earnings press release.
In the upcoming fiscal year 2026, Steris foresees revenue growth between 6-7% and an adjusted EPS ranging from $9.90 to $10.15, indicating continued business expansion and growth prospects. This optimistic outlook further demonstrates the potential for investing in Steris' business.
